Instrument Inactif

Communiqués Almirall SA CBOE EUROPE EQUITIES

Actions

ES0157097017

Produits pharmaceutiques

Temps réel estimé Tradegate Autres places de cotation 08:24:19 05/08/2026
11,07 ^EUR	0,00%

24/07	Almirall, S.A. publie ses résultats pour le premier semestre clos le 30 juin 2026	CI
24/07	Transcript : Almirall, S.A., H1 2026 Earnings Call, Jul 24, 2026

Communiqués

24/07	Almirall H1 2026 Results	BU
20/07	Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older	BU
11/05	Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business	BU
13/04	Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology	BU
30/03	Almirall enters collaboration with Huaota for the development of a novel monoclonal antibody in medical dermatology	AQ
27/03	Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis	BU
26/03	AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne	BU
23/03	Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology	BU
12/03	Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships	BU
23/02	Almirall’s 2025 Results	BU
29/01	Almirall Announces the Approval of Seysara® in China for the Treatment of Moderate-to-Severe Acne	BU
15/01	Almirall Announces 'LumiNE', a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema	AQ
15/01	Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema	BU
14/01	Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference	BU
10/11	Almirall’s 2025 9M Results	BU
28/07/25	Almirall H1 2025 Results, Almirall Continues to Deliver on its Long-Term Growth Strategy with Net Sales Growth of 12.7% in H1 2025, Driven by a Strong European Dermatology Business and Increasing Biologics Sales	AQ
25/07/25	Almirall H1 2025 Results	BU
12/05/25	Almirall Q1 2025 Results	BU
05/05/25	Almirall S A : and Biofrontera Launch the ‘Hats On’ Challenge to Raise Awareness and Support for Actinic Keratosis	PU
21/03/25	Almirall's 16th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology	BU
07/03/25	AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satisfaction with Tirbanibulin	BU
06/03/25	Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025	BU
25/02/25	Almirall surpassed guidance for 2024, entering an era of sustained growth and further advancing its Medical Dermatology pipeline	AQ
24/02/25	Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline	BU
15/01/25	Almirall at the JPMorgan Conference, entering a new era of sustained growth	AQ